

**Forum for Collaborative HIV Research**

**Mechanisms and Pharmacodynamics Underlying Increased Risk of Cardiovascular Disease**

May 12, 2010  
Artemis Hotel  
Amsterdam, Netherlands

Meeting Agenda

<b>May 11, 2010</b>		
7:30 p.m.	Dinner for participants at Artemis	
<b>May 12, 2010</b>		
<b>Session I: Goals and Objectives</b> Moderator: Russ Tracy, Jur Strobos		
8:30-9:00 a.m.	Breakfast	
9:00-9:15 a.m.	Introduction	Jur Strobos (Forum)
	Goals & Objectives	Russ Tracy
	Report from Roundtable 1	Kendall Marcus
<b><u>Session II: Theories of Cardiovascular Risk in Patients Infected with HIV</u></b> <b>Objective: Understanding of current literature and hypotheses</b> Moderator: Peter Reiss		
9:15-9:35 a.m.	Mechanisms of risk related to HIV infection: immune activation	Russ Tracy
9:35-9:55 a.m.	Mechanisms of risk related to drug intervention: toxicity, mechanisms of action, immune activation	Bill Powderly
9:55-10:00 a.m.	Clinical comment – cardiology perspective	Nisha Chandra-Strobos
10:00-10:30 a.m.	<u>Moderated Participant Discussion</u> How well established are these mechanisms? Do clinical data support these mechanisms?	All
10:30-10:45 a.m.	Coffee Break	
<b><u>Session III: Pharmacodynamics and Pharmacogenetics – Impact on Risk Assessment</u></b> <b>Objective: Understanding mechanisms to isolate drug impact</b> Moderator: Courtney Fletcher		
10:45-11:00 a.m.	Opening remarks	Courtney Fletcher
11:00-11:30 a.m.	<u>Moderated Panel Discussion:</u> ART drug kinetics, tissue levels and genomics In vitro and animal models Gaps in knowledge that can be addressed?	<u>Panelists:</u> Karin Klingman Jean Tschampa Ivona Pandrea Kendall Marcus Mark van der Laan

**Session IV: Interactions of HIV and ARV Mechanisms with Traditional Risk Factors**

**Objective: Understand the influence of HIV and/or ARVs on traditional risk factors**

Moderator: Frank Boccara, Maya Petersen

11:15-12:15 p.m.	<u>Moderated Panel Discussion</u> Lipid profiles Platelet activation Renal, metabolic or cardiac drug toxicity Relative demographic risk (e.g., obesity, ethnicity) Do ARVs insufficiently suppress HIV related risk? Do differing mechanisms of ARV activity or pharmacodynamics influence CV risk disparately?  Gaps in knowledge that can be addressed?	<u>Panelists:</u> Caroline Sabin Giovanni Guaraldi Ivona Pandrea Paddy Mallon Filip Josephson
------------------	--	--

12:15-1:00 p.m. Lunch

**Session V: Biomarkers & Signals**

**Objective: Identify potentially useful biomarkers for risk**

Moderator: Michael Lederman

1:00-2:00 p.m.	<u>Moderated Panel Discussion:</u> Currently identified biomarkers Associated or causal? Validating predictiveness Standardization of methods Lessons from other disease areas?  Gaps in knowledge  Recommended Next Steps	<u>Panelists:</u> Alan Landay Dominique Costagliola Quazi Ataher Peter Reiss
----------------	---	--

**Session VI: Building a research agenda**

**Objective: Develop recommendations**

Moderator: Jur Strobos

2:00-3:00 p.m.	<u>Moderated Participant Discussion</u> Separating effects of chronic infection vs ART Role of HIV in development and progression of atherosclerosis Characterization of plaques in HIV infected vs non-infected individuals Identification of relevant predictive biomarkers  Role of in vitro and animal model  Research Plan	All
----------------	---	-----

3:00-3:15 p.m.	Coffee Break	
<b><u>Session VII: Wrap-Up</u></b> Moderator: Veronica Miller		
3:15-3:30 p.m.	Summary	
3:30-4:00 p.m.	Recommended next steps and final comments Adjournment	All